Cardinal Health has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors’ coronary stent portfolio. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia and New Zealand. This marks Cordis’ return to the drug-eluting stent market and the beginning of a partnership between Cardinal Health and Biosensors.
Cordis will now offer an expanded portfolio of products in select countries for the treatment of patients undergoing percutaneous coronary intervention, from access to intervention and closure.
David Wilson, president of Cordis, says, “Partnerships like this provide an opportunity to rapidly expand our portfolio.”
In the next few months, Cordis will begin offering Biosensors’ coronary stent portfolio, which includes the BioFreedom polymer-free drug-coated stent; the BioMatrix NeoFlex drug-eluting stent; BioMatrix Alpha, a cobalt chromium drug-eluting stent with an abluminal bioabsorbable coating; and the Chroma cobalt chromium bare metal stent, in select European countries, Australia and New Zealand. Over time, Cordis will begin to sell these products under the LUMENO private label in select countries, and both companies will continue to distribute products in additional European countries, the Middle East, Africa and other parts of the world.
Biosensors’ drug-eluting stent with a bio-absorbable coating and the Biolimus A9 drug are supported by multiple large-scale studies, including data from LEADERS, a prospective, randomised, multicentre clinical trial that demonstrated that the safety and efficacy of Biosensors’ BioMatrix Flex stent is comparable to that of a durable polymer drug-eluting stent in a population of 1,707 patients across 10 European centres.
Additionally, data published in the New England Journal of Medicine from LEADERS FREE—a prospective, double-blind, randomised clinical trial exclusively focusing on patients at high-bleeding risk receiving only one month of dual anti-platelet therapy—demonstrated superiority with respect to the primary safety and efficacy endpoints for BioFreedom as compared to a bare metal stent in patients undergoing percutaneous coronary intervention. The trial assessed the shortest course of dual anti-platelet therapy ever used with an active stent. LEADERS FREE included 2,466 patients across 68 sites in 20 countries in Europe, Asia, Australia and Canada, with a follow-up phase of two years.